vs
Side-by-side financial comparison of ACNB CORP (ACNB) and Cytek Biosciences, Inc. (CTKB). Click either name above to swap in a different company.
Cytek Biosciences, Inc. is the larger business by last-quarter revenue ($62.1M vs $47.2M, roughly 1.3× ACNB CORP). ACNB CORP runs the higher net margin — 22.9% vs -70.9%, a 93.8% gap on every dollar of revenue. On growth, ACNB CORP posted the faster year-over-year revenue change (42.2% vs 8.1%). ACNB CORP produced more free cash flow last quarter ($52.6M vs $-1.8M). Over the past eight quarters, ACNB CORP's revenue compounded faster (22.1% CAGR vs 17.7%).
ACNB Corp is a US-based financial holding company headquartered in Pennsylvania. It provides a full suite of financial solutions including retail and commercial banking, wealth management, trust services, and property & casualty insurance products. Its core market covers local communities, individual consumers, and small-to-medium enterprises across south-central Pennsylvania and northern Maryland.
Cytek Biosciences, Inc. develops, manufactures and sells high-performance flow cytometry systems, associated reagents and analysis software. Its solutions serve life science research, clinical diagnostics and biopharmaceutical sectors, with a global customer base across North America, Europe and the Asia-Pacific region.
ACNB vs CTKB — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $47.2M | $62.1M |
| Net Profit | $10.8M | $-44.1M |
| Gross Margin | — | 52.9% |
| Operating Margin | 27.9% | -9.0% |
| Net Margin | 22.9% | -70.9% |
| Revenue YoY | 42.2% | 8.1% |
| Net Profit YoY | 63.8% | -557.1% |
| EPS (diluted) | $1.10 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $47.2M | $62.1M | ||
| Q3 25 | $50.9M | $52.3M | ||
| Q2 25 | $50.3M | $45.6M | ||
| Q1 25 | $43.5M | $41.5M | ||
| Q4 24 | $33.2M | $57.5M | ||
| Q3 24 | $34.1M | $51.5M | ||
| Q2 24 | $33.3M | $46.6M | ||
| Q1 24 | $31.6M | $44.9M |
| Q4 25 | $10.8M | $-44.1M | ||
| Q3 25 | $14.9M | $-5.5M | ||
| Q2 25 | $11.6M | $-5.6M | ||
| Q1 25 | $-272.0K | $-11.4M | ||
| Q4 24 | $6.6M | $9.6M | ||
| Q3 24 | $7.2M | $941.0K | ||
| Q2 24 | $11.3M | $-10.4M | ||
| Q1 24 | $6.8M | $-6.2M |
| Q4 25 | — | 52.9% | ||
| Q3 25 | — | 52.7% | ||
| Q2 25 | — | 52.3% | ||
| Q1 25 | — | 48.6% | ||
| Q4 24 | — | 58.5% | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 54.6% | ||
| Q1 24 | — | 51.3% |
| Q4 25 | 27.9% | -9.0% | ||
| Q3 25 | 37.2% | -17.6% | ||
| Q2 25 | 29.7% | -23.3% | ||
| Q1 25 | -1.3% | -36.1% | ||
| Q4 24 | 24.8% | 5.2% | ||
| Q3 24 | 27.6% | -8.2% | ||
| Q2 24 | 42.8% | -18.3% | ||
| Q1 24 | 26.9% | -23.9% |
| Q4 25 | 22.9% | -70.9% | ||
| Q3 25 | 29.2% | -10.5% | ||
| Q2 25 | 23.2% | -12.2% | ||
| Q1 25 | -0.6% | -27.5% | ||
| Q4 24 | 19.9% | 16.8% | ||
| Q3 24 | 21.1% | 1.8% | ||
| Q2 24 | 33.9% | -22.4% | ||
| Q1 24 | 21.4% | -13.8% |
| Q4 25 | $1.10 | — | ||
| Q3 25 | $1.42 | — | ||
| Q2 25 | $1.11 | — | ||
| Q1 25 | $-0.03 | — | ||
| Q4 24 | $0.77 | — | ||
| Q3 24 | $0.84 | — | ||
| Q2 24 | $1.32 | — | ||
| Q1 24 | $0.80 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $65.6M | $90.9M |
| Total DebtLower is stronger | $255.4M | — |
| Stockholders' EquityBook value | $420.0M | $341.7M |
| Total Assets | $3.2B | $461.5M |
| Debt / EquityLower = less leverage | 0.61× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $65.6M | $90.9M | ||
| Q3 25 | $102.1M | $93.3M | ||
| Q2 25 | $103.1M | $75.5M | ||
| Q1 25 | $123.6M | $95.3M | ||
| Q4 24 | $47.3M | $98.7M | ||
| Q3 24 | $58.1M | $162.3M | ||
| Q2 24 | $86.3M | $177.9M | ||
| Q1 24 | $53.1M | $168.8M |
| Q4 25 | $255.4M | — | ||
| Q3 25 | $255.4M | — | ||
| Q2 25 | $255.4M | — | ||
| Q1 25 | $255.3M | — | ||
| Q4 24 | $255.3M | — | ||
| Q3 24 | $255.3M | — | ||
| Q2 24 | $255.3M | — | ||
| Q1 24 | $255.3M | — |
| Q4 25 | $420.0M | $341.7M | ||
| Q3 25 | $408.6M | $378.6M | ||
| Q2 25 | $395.2M | $377.6M | ||
| Q1 25 | $386.9M | $379.6M | ||
| Q4 24 | $303.3M | $395.7M | ||
| Q3 24 | $306.8M | $385.5M | ||
| Q2 24 | $289.3M | $389.1M | ||
| Q1 24 | $279.9M | $392.6M |
| Q4 25 | $3.2B | $461.5M | ||
| Q3 25 | $3.3B | $494.9M | ||
| Q2 25 | $3.3B | $493.3M | ||
| Q1 25 | $3.3B | $482.6M | ||
| Q4 24 | $2.4B | $499.5M | ||
| Q3 24 | $2.4B | $491.2M | ||
| Q2 24 | $2.5B | $483.7M | ||
| Q1 24 | $2.4B | $492.1M |
| Q4 25 | 0.61× | — | ||
| Q3 25 | 0.62× | — | ||
| Q2 25 | 0.65× | — | ||
| Q1 25 | 0.66× | — | ||
| Q4 24 | 0.84× | — | ||
| Q3 24 | 0.83× | — | ||
| Q2 24 | 0.88× | — | ||
| Q1 24 | 0.91× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $53.6M | $-771.0K |
| Free Cash FlowOCF − Capex | $52.6M | $-1.8M |
| FCF MarginFCF / Revenue | 111.4% | -2.9% |
| Capex IntensityCapex / Revenue | 2.3% | 1.6% |
| Cash ConversionOCF / Net Profit | 4.96× | — |
| TTM Free Cash FlowTrailing 4 quarters | $92.2M | $-8.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $53.6M | $-771.0K | ||
| Q3 25 | $23.2M | $-3.9M | ||
| Q2 25 | $17.8M | $108.0K | ||
| Q1 25 | $-71.0K | $-125.0K | ||
| Q4 24 | $39.8M | $2.0M | ||
| Q3 24 | $13.6M | $13.2M | ||
| Q2 24 | $9.7M | $6.2M | ||
| Q1 24 | $10.8M | $4.0M |
| Q4 25 | $52.6M | $-1.8M | ||
| Q3 25 | $22.8M | $-4.6M | ||
| Q2 25 | $17.6M | $-1.5M | ||
| Q1 25 | $-730.0K | $-974.0K | ||
| Q4 24 | $38.8M | $1.1M | ||
| Q3 24 | $13.3M | $12.2M | ||
| Q2 24 | $9.4M | $5.2M | ||
| Q1 24 | $10.7M | $3.4M |
| Q4 25 | 111.4% | -2.9% | ||
| Q3 25 | 44.7% | -8.7% | ||
| Q2 25 | 35.0% | -3.2% | ||
| Q1 25 | -1.7% | -2.3% | ||
| Q4 24 | 117.0% | 1.9% | ||
| Q3 24 | 39.1% | 23.7% | ||
| Q2 24 | 28.3% | 11.0% | ||
| Q1 24 | 33.9% | 7.6% |
| Q4 25 | 2.3% | 1.6% | ||
| Q3 25 | 0.8% | 1.3% | ||
| Q2 25 | 0.4% | 3.5% | ||
| Q1 25 | 1.5% | 2.0% | ||
| Q4 24 | 2.9% | 1.6% | ||
| Q3 24 | 0.7% | 2.0% | ||
| Q2 24 | 0.9% | 2.3% | ||
| Q1 24 | 0.2% | 1.3% |
| Q4 25 | 4.96× | — | ||
| Q3 25 | 1.56× | — | ||
| Q2 25 | 1.52× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 6.03× | 0.21× | ||
| Q3 24 | 1.88× | 14.05× | ||
| Q2 24 | 0.86× | — | ||
| Q1 24 | 1.60× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACNB
Segment breakdown not available.
CTKB
| Products | $46.6M | 75% |
| Services | $15.5M | 25% |
